1.13
+0.7133(+171.67%)
Currency In USD
| Previous Close | 0.42 |
| Open | 1.26 |
| Day High | 1.39 |
| Day Low | 0.97 |
| 52-Week High | 3.65 |
| 52-Week Low | 0.37 |
| Volume | 344.77M |
| Average Volume | 531,587 |
| Market Cap | 16.37M |
| PE | -0.81 |
| EPS | -1.38 |
| Moving Average 50 Days | 0.85 |
| Moving Average 200 Days | 0.92 |
| Change | 0.7 |
If you invested $1000 in Imunon, Inc. (IMNN) 10 years ago, it would be worth $1.98 as of May 23, 2025 at a share price of $1.09. Whereas If you bought $1000 worth of Imunon, Inc. (IMNN) shares 5 years ago, it would be worth $24.06 as of May 23, 2025 at a share price of $1.09.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer
GlobeNewswire Inc.
7 hours ago
Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group Women treated with IMNN-001 and standard of care chemotherapy plus PARP inh
IMUNON Announces Withdrawal of Form S-1 Registration Statement
GlobeNewswire Inc.
Yesterday at 9:20 PM GMT
LAWRENCEVILLE, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has filed a request for withdrawal with the Securities a
IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19
GlobeNewswire Inc.
May 15, 2025 12:05 PM GMT
Company’s PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines Results further validate PlaCCine as a novel vaccine platform with potential applications in COVID-19 and other infectious diseases